Catalyst Pharmaceuticals Management
Management criteria checks 2/4
Catalyst Pharmaceuticals' CEO is Rich Daly, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.2% of the company’s shares, worth $5.18M. The average tenure of the management team and the board of directors is 4 years and 12 years respectively.
Key information
Rich Daly
Chief executive officer
US$14.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | 4yrs |
| Board average tenure | 12yrs |
Recent management updates
Recent updates
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve
Nov 13
Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings
Nov 07Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Jul 24Catalyst Pharmaceuticals: New Products In Proving Phase
Jul 06Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
Apr 06Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Jan 29Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk
Jan 17With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case
Sep 06Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?
May 27Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?
Feb 13Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?
Nov 11CEO
Rich Daly (63 yo)
less than a year
Tenure
US$14,076,923
Compensation
Mr. Richard John Daly, also known as Rich, MBA, had been an Independent Director at Catalyst Pharmaceuticals, Inc. from February 2015 until January 1, 2024 and serves as its Chief Executive Officer and Dir...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$14.08m | 0.20% $ 5.2m | |
| Executive VP | 15.2yrs | US$3.40m | 0.58% $ 15.2m | |
| Chief Medical & Regulatory Officer | 9.5yrs | US$2.37m | 0.047% $ 1.2m | |
| Executive VP & Chief Commercial Officer | 4.5yrs | US$2.51m | 0.015% $ 398.5k | |
| Executive VP | less than a year | no data | no data | |
| VP & Head of Investor Relations | 3.3yrs | no data | no data | |
| Chief Compliance Officer & Chief Legal Officer | 8.8yrs | US$353.27k | 0.15% $ 3.9m | |
| Vice President of Sales | 4.5yrs | no data | no data | |
| Senior Vice President of Medical Affairs & Drug Discovery | 1.8yrs | no data | no data | |
| Chief Strategy Officer | 3.4yrs | US$1.70m | 0.025% $ 661.8k | |
| Corporate Secretary | no data | no data | no data |
4.0yrs
Average Tenure
61yo
Average Age
Experienced Management: CPRX's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.8yrs | US$14.08m | 0.20% $ 5.2m | |
| Independent Director | 22.2yrs | US$370.99k | 0.29% $ 7.7m | |
| Co-Founder & Chairman | 22.9yrs | US$2.15m | 3.76% $ 98.9m | |
| Independent Director | 9.8yrs | US$376.24k | 0.37% $ 9.7m | |
| Lead Independent Director | 20yrs | US$397.24k | 0.61% $ 16.0m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.5yrs | US$363.12k | 0.0012% $ 31.1k | |
| Member of Scientific Advisory Board | 14.1yrs | no data | no data | |
| Independent Director | 1.6yrs | US$610.43k | 0.0012% $ 31.1k |
12.0yrs
Average Tenure
63yo
Average Age
Experienced Board: CPRX's board of directors are seasoned and experienced ( 12 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 22:38 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Catalyst Pharmaceuticals, Inc. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Jason Matthew Gerberry | BofA Global Research |
| Charles Duncan | Cantor Fitzgerald & Co. |